Freenome Launches Multi-Cancer Detection Study Pairing Multiomics with Real-World Data

Freenome, a privately held biotech company, today announced the launch of the Sanderson Study, the company’s latest study of its multiomics platform, in combination with real-world data to detect multiple cancers.

Related Keywords

United States , Tim Sanderson , Cerner Enviza , Christy Dueck , Elligo Health Research , Health Network , Oracle , Should Know , Sanderson Study , Comprehensive Multiomics Platform , Early Detection , Oracle Cerner , Learning Health Network ,